Drug Shortage Report for TEVETEN
Report ID | 171165 |
Drug Identification Number | 02240432 |
Brand name | TEVETEN |
Common or Proper name | EPROSARTAN |
Company Name | BGP PHARMA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | EPROSARTAN |
Strength(s) | 400MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 2x14 |
ATC code | C09CA |
ATC description | ANGIOTENSIN II ANTAGONISTS, PLAIN |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-01-03 |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2022-10-05 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2022-10-05 | French | Compare |
v1 | 2022-10-05 | English | Compare |
Showing 1 to 2 of 2